Systemic sclerosis (scleroderma) trials in United States

In United States 53 Also abroad 213

39 of 53 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Where
Atlanta, Baltimore, Bethesda, Birmingham, Boston, Chicago, City of Saint Peters, Columbus, Creve Coeur, Dallas, Detroit, Fairway, Fort Worth, Hays, Houston, Kansas City, Lawrence, Lee's Summit, Lexington, Mineola, New Brunswick, New Haven, New York, North Kansas City, Olathe, Overland Park, Palo Alto, Philadelphia, Pittsburg, Pittsburgh, Richardson, Richmond, Sacramento, Salina, Salt Lake City, St Louis, Topeka, Washington D.C., Westwood
Age
18 years and over
People
300 worldwide
Run by
National Cancer Institute (NCI)
See details and how to joinNCT03816345
Phase 1/2Taking people
A Study of AZD0120 in Autoimmune Diseases
Where
Ann Arbor, Baltimore, Chapel Hill, Chicago, Duarte, Miami, New York, Seattle, Stanford, St Louis, Tucson
Age
18 years to 75 years
People
27 worldwide
Run by
AstraZeneca
See details and how to joinNCT07295847
Phase 3Taking people
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Where
Ann Arbor, Baltimore, Boca Raton, Boston, Charleston, Charlotte, Chicago, Cleveland, Columbus, Dallas, Fort Lauderdale, Indianapolis, Irvine, Los Angeles, New York, Omaha, Phoenix, Portland, Roanoke, Rochester, San Francisco
Age
5 years to 80 years
People
1,072 worldwide
Run by
AstraZeneca
See details and how to joinNCT07691970
Phase 2Not yet taking people in United States
FAPI PET in Systemic Sclerosis Interstitial Lung Disease
Where
Los Angeles
Age
18 years and over
People
120
Run by
University of California, Los Angeles
See details and how to joinNCT07925242
Phase 2Not yet taking people in United States
Hyaluronidase Injections for Sclerodactyly in Patients With Scleroderma
Where
Stanford
Age
18 years and over
People
10
Run by
Stanford University
See details and how to joinNCT07916324
Phase 1/2Taking people
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Where
Houston
Age
18 years and over
People
47
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT06434363
Phase 1Taking people
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Where
Aurora, Baltimore, Charleston, Charlotte, Chicago, Durham, East Brunswick, Greenville, Iowa City, Jacksonville, Kansas City, Loma Linda, Louisville, New York, Phoenix, Salt Lake City, Valhalla
Age
18 years to 74 years
People
66 worldwide
Run by
Allogene Therapeutics
See details and how to joinNCT07085104
Phase 1/2Taking people
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Where
Ann Arbor, Charlotte, Dallas, Fairway, Hackensack, Los Angeles, Minneapolis, New York, Plantation, Summit, Syracuse, Tampa
Age
18 years to 75 years
People
240
Run by
Nkarta, Inc.
See details and how to joinNCT06733935
Phase 1Taking people
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Where
Boston, Chapel Hill, Chicago, Iowa City, La Jolla, New Orleans, Portland, Redwood City, St Louis
Age
18 years to 70 years
People
80 worldwide
Run by
CRISPR Therapeutics
See details and how to joinNCT06925542
Phase 2/3Taking people
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Where
Ann Arbor, Chicago, Durham, Jacksonville, Kansas City, New Haven, New York, Rochester
Age
18 years to 75 years
People
37
Run by
Cabaletta Bio
See details and how to joinNCT06328777
Early phase 1Not yet taking people in United States
Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial
Where
Charleston
Age
18 years to 60 years
People
10
Run by
Medical University of South Carolina
See details and how to joinNCT07697274
Phase 3Taking people
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Where
Ann Arbor, Aurora, Austin, Baltimore, Birmingham, Boston, Chicago, Frisco, Houston, Jackson, Los Angeles, Minneapolis, New Brunswick, New Orleans, New York, Ormond Beach, Philadelphia, Phoenix, Plantation, Saint Clair Shores, San Diego, Scottsdale, South Miami, Stanford, Washington D.C., Whittier
Age
18 years and over
People
448 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07497087 · EU 2025-523884-39-00
Phase 1Not yet taking people in United States
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Where
Ann Arbor, Great Neck, Morristown, Newport Beach, Omaha, Philadelphia, Saint Paul, Salt Lake City, Seattle, Worcester
Age
18 years and over
People
60 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07873931
Phase 1Not yet taking people in United States
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy
Where
Gilbert
Age
18 years to 70 years
People
12
Run by
AbelZeta Inc.
See details and how to joinNCT07854483
Phase 2Taking people
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Where
Allen, Aurora, Baltimore, Boston, Brooklyn, Clearwater, Cleveland, Dallas, Houston, Kansas City, La Jolla, Loma Linda, Los Angeles, Minneapolis, Newport Beach, Oklahoma City, Palo Alto, Philadelphia, Phoenix, Pittsburgh, Sarasota, Tampa
Age
18 years and over
People
85 worldwide
Run by
Mediar Therapeutics
See details and how to joinNCT07287670
Phase 2Taking people
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
Where
Baltimore, New Orleans
Age
18 years and over
People
30
Run by
Johns Hopkins University
See details and how to joinNCT04797286
Phase 1Enrolling by invitation
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
Where
Duarte, New York, Stanford, Tampa
Age
18 years and over
People
52 worldwide
Run by
Kite, A Gilead Company
See details and how to joinNCT07038447
Phase 3Not yet taking people in United States
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
Where
Ann Arbor, Atlanta, Aurora, Charleston, Chicago, Cleveland, Dallas, Denver, Houston, Miami, Philadelphia, Pittsburgh, Rochester, Scottsdale, Seattle, Summit, Worcester
Age
16 years and over
People
92 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07335562 · EU 2025-524337-11-00
Phase 3Taking people
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
Where
Los Angeles, New York, Philadelphia
Age
18 years and over
People
514 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06716606
Phase 2/3Taking people
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Where
Ann Arbor, Aurora, Baltimore, Chicago, Cincinnati, Denison, El Paso, Houston, Jacksonville, Los Angeles, Miami, New Brunswick, New York, Philadelphia, Phoenix, Pittsburgh, Potsdam, Scottsdale, Tucson, Upland, Washington D.C.
Age
18 years and over
People
300 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT05878717 · EU 2023-503219-14-01
Phase 1/2Taking people
FT839 in Autoimmune Diseases
Where
Fullerton
Age
18 years to 70 years
People
446
Run by
Fate Therapeutics
See details and how to joinNCT07800871
Phase 2Taking people
Platform Clinical Study for Conquering Scleroderma
Where
Ann Arbor, Atlanta, Baltimore, Birmingham, Boston, Charleston, Chicago, Cleveland, Durham, Great Neck, Houston, Kansas City, Los Angeles, Milwaukee, Nashville, New Brunswick, New Haven, New York, Palo Alto, Philadelphia, Pittsburgh, Portland, Rochester, Salt Lake City, St Louis, Washington D.C.
Age
18 years and over
People
400 worldwide
Run by
Scleroderma Research Foundation, Inc.
See details and how to joinNCT06195072 · EU 2023-507129-40-00
Phase 2Taking people
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
Where
Pittsburgh
Age
8 years to 60 years
People
8
Run by
Paul Szabolcs
See details and how to joinNCT03630211
Phase 2Taking people
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Where
Arlington, Bellaire, Charleston, Charlotte, Chula Vista, Covina, Gainesville, Great Falls, Hixson, Iowa City, Irving, Jackson, Jupiter, Katy, Los Alamitos, Los Angeles, Mesquite, Miami, Norcross, Phoenix, Plantation, Red Oak, Roanoke, Santa Ana, Statesville, Tucson, Tuscaloosa, Tustin, Willowbrook, Woodland
Age
18 years and over
People
90 worldwide
Run by
Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00
Phase 1Not yet taking people in United States
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease
Where
Boston
Age
16 years to 75 years
People
94
Run by
Luminary Therapeutics
See details and how to joinNCT07729995